← Back to Clinical Trials
Recruiting NCT06382519

NCT06382519 Thalidomide Therapy for VEOIBD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06382519
Status Recruiting
Phase
Sponsor Children's Hospital of Fudan University
Condition Inflammatory Bowel Diseases
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2024-05-15
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 28 Days
Max Age 6 Years
Study Type OBSERVATIONAL
Interventions
Thalidomide

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2024-05-15 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease

Eligibility Criteria

Inclusion Criteria: * diagnosed with inflammatory bowel disease * disease onset less than 6 years old * Pediatric Crohn's disease Activity Index (PCDAI)\>30 or Pediatric Ulcerative Colitis Activity Index (PUCAI)\>35 * patients and their legal guardians were willing to receive thalidomide treatment and participate in this study. Exclusion Criteria: * liver dysfunction * allergy to thalidomide * with Neuropathy * with thrombosis * thalidomide treatment in the previous 30 days * biologics treatment in the previous 8 weeks * not suitable participated in this study

Contact & Investigator

Central Contact

Ying Huang

✉ yhuang815@163.com

📞 021-64931727

Principal Investigator

Ying Huang

PRINCIPAL INVESTIGATOR

Children's Hospital of Fudan University

Frequently Asked Questions

Who can join the NCT06382519 clinical trial?

This trial is open to participants of all sexes, aged 28 Days or older, up to 6 Years, studying Inflammatory Bowel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06382519 currently recruiting?

Yes, NCT06382519 is actively recruiting participants. Contact the research team at yhuang815@163.com for enrollment information.

Where is the NCT06382519 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT06382519 clinical trial?

NCT06382519 is sponsored by Children's Hospital of Fudan University. The principal investigator is Ying Huang at Children's Hospital of Fudan University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology